EUVIMEDEUVIMED entdecken
Crossref

Nonpersistent Nanoarchitectures Enhance Concurrent Chemoradiotherapy in an Immunocompetent Orthotopic Model of HPV+ Head/Neck Carcinoma

Alessandra Gonnelli, Marine Gerbé de Thoré, Maria Laura Ermini, Valentina Frusca, Agata Zamborlin, Nicolas Signolle, Olivia Bawa, Céline Clémenson, Lydia Meziani, Paul Bergeron, Ismail El-Azrak, Patrizia Sarogni und 7 weitere

Advanced Materials · 2024

DOI: 10.1002/adma.202400949 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Materials, 2024. Verfasst von Alessandra Gonnelli und 18 weiteren Autor:innen. Beteiligte Einrichtung: Center for Nanotechnology Innovation@NEST, Istituto Italiano di Tecnologia, Piazza San Silvestro 12, Pisa, 56127, Italy. Hauptthemen laut MEDLINE: Chemoradiotherapy, Head and Neck Neoplasms, Cisplatin, Gold. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: MFAG, Associazione Italiana per la Ricerca sul Cancro, Inserm Transfert.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cisplatin chemoradiotherapy (CRT) is the established standard of care for managing locally advanced human papillomavirus‐positive head/neck carcinoma. The typically young patients may suffer serious and long‐time side effects caused by the treatment, such as dysphagia, and hearing loss. Thus, ensuring a satisfactory post‐treatment quality of life is paramount. One potential replacing approach to the classical CRT involves the combination of standard‐dose radiotherapy and radiosensitizers such as noble metal nanoparticles (NPs). However, several concerns about size, shape, and biocompatibility limit the translation of metal nanomaterials to the clinical practice. Here, it is demonstrated that a new model of nonpersistent gold nanoarchitectures containing cisplatin (NAs‐Cluster‐CisPt) generates, in combination with radiotherapy, a significant in vivo tumor‐reducing effect compared to the standard CRT, achieving a complete tumor clearance in 25% of the immunocompetent models that persist for 60 days. These findings, together with the negligible amount of metals recognized in the excretory organs, highlight that the concurrent administration of NAs‐Cluster‐CisPt and radiotherapy has the potential to overcome some clinical limitations associated to NP‐based approaches while enhancing the treatment outcome with respect to standard CRT. Overall, despite further mechanistic investigations being essential, these data support the exploiting of nonpersistent metal‐nanomaterial‐mediated approaches for oral cancer management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ChemoradiotherapyHead and Neck NeoplasmsCisplatinGoldAnimalsMiceHumansCell Line, TumorMetal NanoparticlesAntineoplastic AgentsPapillomavirus InfectionsNanostructuresImmunocompetencePapillomaviridae

Stichwörter der Autor:innen

chemoradiotherapycombined therapygold nanoparticleshead and neck carcinomaradiosensitization

Substanzen

CisplatinGoldAntineoplastic Agents

Autor:innen und Institutionen

  • Center for Nanotechnology Innovation@NEST, Istituto Italiano di Tecnologia, Piazza San Silvestro 12, Pisa, 56127, Italy.
  • Radiation Oncology Unit, Pisa University Hospital "Azienda Ospedaliero-Universitaria Pisana", Via Roma 67, Pisa, 56126, Italy.
  • Gustave Roussy, INSERM U1030 Molecular Radiotherapy and Therapeutic Innovation, Université Paris Saclay, 114, rue Edouard Vaillant, Villejuif Cedex, 94805, France.
  • Scuola Superiore Sant'Anna, Piazza Martiri della Libertà 33, Pisa, 56127, Italy.
  • NEST-Scuola Normale Superiore, Piazza San Silvestro 12, Pisa, 56127, Italy.
  • Gustave Roussy, Plateforme de pathologie expérimentale et translationnelle, UMS AMMICA, 114, rue Edouard Vaillant, Villejuif Cedex, 94805, France.

ORCID-Profile: Valerio Voliani

Förderung

  • MFAG
  • Associazione Italiana per la Ricerca sul Cancro
  • Inserm Transfert
  • SIRIC SOCRATE
  • Institut National Du Cancer

Zitieren

APA

Gonnelli, A., Gerbé de Thoré, M., Ermini, M. L., Frusca, V., Zamborlin, A., Signolle, N., Bawa, O., Clémenson, C., Meziani, L., Bergeron, P., El-Azrak, I., Sarogni, P., Mugnaioli, E., Giannini, N., Drava, G., Deutsch, E., Paiar, F., Mondini, M., & Voliani, V. (2024). Nonpersistent Nanoarchitectures Enhance Concurrent Chemoradiotherapy in an Immunocompetent Orthotopic Model of HPV+ Head/Neck Carcinoma. Advanced Materials. https://doi.org/10.1002/adma.202400949

Vancouver

Gonnelli A, Gerbé de Thoré M, Ermini ML, Frusca V, Zamborlin A, Signolle N, et al. Nonpersistent Nanoarchitectures Enhance Concurrent Chemoradiotherapy in an Immunocompetent Orthotopic Model of HPV+ Head/Neck Carcinoma. Advanced Materials. 2024. doi:10.1002/adma.202400949

BibTeX
@article{Gonnelli2024,
  author = {Gonnelli, Alessandra and Gerbé de Thoré, Marine and Ermini, Maria Laura and Frusca, Valentina and Zamborlin, Agata and Signolle, Nicolas and Bawa, Olivia and Clémenson, Céline and Meziani, Lydia and Bergeron, Paul and El-Azrak, Ismail and Sarogni, Patrizia and Mugnaioli, Enrico and Giannini, Noemi and Drava, Giuliana and Deutsch, Eric and Paiar, Fabiola and Mondini, Michele and Voliani, Valerio},
  title = {Nonpersistent Nanoarchitectures Enhance Concurrent Chemoradiotherapy in an Immunocompetent Orthotopic Model of HPV+ Head/Neck Carcinoma},
  journal = {Advanced Materials},
  year = {2024},
  doi = {10.1002/adma.202400949}
}
Kostenlos starten →